AYX - looking to make another strong run
Updated
The fundamentals:
Alteryx delivered another strong quarter, despite fears that growth is slowing. However, the stock price fell back down after a short run-up to earnings. Long term, AYX still looks good and will likely continue to deliver strong results.
The technicals:
RSI is hovering around 50, signaling a decent entry point. It is currently trading around 13% down from the ATH of $39.21. EMA50 has always been above EMA200 (although the IPO was only about a year ago), signaling that the bullish momentum is strong. Implied volatility (IV30) is around 50 - while this is relatively low for AYX, it does also make options riskier compared to your typical blue-chips.
The play:
Short term target: $38
Long term: expect new ATH by the next earnings report if Alteryx maintains this momentum. Covered calls/"poor man's covered calls" is a good play, given the currently "low" IV.
Alteryx delivered another strong quarter, despite fears that growth is slowing. However, the stock price fell back down after a short run-up to earnings. Long term, AYX still looks good and will likely continue to deliver strong results.
The technicals:
RSI is hovering around 50, signaling a decent entry point. It is currently trading around 13% down from the ATH of $39.21. EMA50 has always been above EMA200 (although the IPO was only about a year ago), signaling that the bullish momentum is strong. Implied volatility (IV30) is around 50 - while this is relatively low for AYX, it does also make options riskier compared to your typical blue-chips.
The play:
Short term target: $38
Long term: expect new ATH by the next earnings report if Alteryx maintains this momentum. Covered calls/"poor man's covered calls" is a good play, given the currently "low" IV.
Note
The last few days have been good. It can make another strong rally if it breaks ATHTrade closed: target reached
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.